Redhill Biopharma (NASDAQ:RDHL) Share Price Passes Below 200-Day Moving Average – What’s Next?

Redhill Biopharma Ltd. (NASDAQ:RDHL) shares crossed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $1.39 and traded as low as $1.04. Redhill Biopharma shares last traded at $1.06, with a volume of 60,111 shares.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Redhill Biopharma in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Redhill Biopharma Price Performance

The firm’s 50 day moving average is $1.21 and its 200 day moving average is $1.39. The company has a market capitalization of $5.42 million, a PE ratio of 0.00 and a beta of 4.91.

Institutional Investors Weigh In On Redhill Biopharma

A hedge fund recently bought a new stake in Redhill Biopharma stock. Gagnon Securities LLC bought a new stake in shares of Redhill Biopharma Ltd. (NASDAQ:RDHL) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 17,822 shares of the biotechnology company’s stock, valued at approximately $39,000. Gagnon Securities LLC owned 0.54% of Redhill Biopharma as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 7.20% of the company’s stock.

Redhill Biopharma Company Profile

RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered small molecules for the treatment of inflammatory, gastrointestinal and oncology indications. Founded in 2009 and headquartered in Tel Aviv, Israel, RedHill is publicly traded on the Nasdaq under the symbol RDHL. The company’s strategy centers on in-licensing late-stage clinical candidates and advancing them through regulatory review toward global commercialization.

RedHill’s lead marketed product, Talicia® (formerly RHB-105), is an FDA-approved, three-drug treatment for Helicobacter pylori infection, co-commercialized in the United States through a partnership with Bausch Health.